Principal Financial Group Inc. decreased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 8.4% in the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,865,346 shares of the biopharmaceutical company’s stock after selling 171,449 shares during the quarter. Principal Financial Group Inc.’s holdings in Gilead Sciences were worth $121,266,000 at the end of the most recent reporting period.
Several other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc boosted its stake in shares of Gilead Sciences by 1.1% during the 3rd quarter. Vanguard Group Inc now owns 97,167,329 shares of the biopharmaceutical company’s stock valued at $7,502,290,000 after buying an additional 1,071,619 shares during the period. Advisors Asset Management Inc. raised its holdings in shares of Gilead Sciences by 45.5% during the 4th quarter. Advisors Asset Management Inc. now owns 91,175 shares of the biopharmaceutical company’s stock valued at $5,703,000 after purchasing an additional 28,507 shares in the last quarter. Greatmark Investment Partners Inc. raised its holdings in shares of Gilead Sciences by 1.6% during the 4th quarter. Greatmark Investment Partners Inc. now owns 95,256 shares of the biopharmaceutical company’s stock valued at $5,958,000 after purchasing an additional 1,470 shares in the last quarter. Wright Investors Service Inc. raised its holdings in shares of Gilead Sciences by 13.2% during the 4th quarter. Wright Investors Service Inc. now owns 12,592 shares of the biopharmaceutical company’s stock valued at $788,000 after purchasing an additional 1,471 shares in the last quarter. Finally, Robecosam AG raised its holdings in shares of Gilead Sciences by 2.6% during the 4th quarter. Robecosam AG now owns 194,273 shares of the biopharmaceutical company’s stock valued at $12,022,000 after purchasing an additional 4,912 shares in the last quarter. Hedge funds and other institutional investors own 78.78% of the company’s stock.
NASDAQ:GILD opened at $66.99 on Friday. Gilead Sciences, Inc. has a 52-week low of $60.32 and a 52-week high of $79.61. The company has a current ratio of 3.62, a quick ratio of 3.53 and a debt-to-equity ratio of 1.09. The stock has a market cap of $85.14 billion, a PE ratio of 10.89, a P/E/G ratio of 0.64 and a beta of 1.10.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.53 by $0.23. Gilead Sciences had a net margin of 26.40% and a return on equity of 37.98%. The company had revenue of $5.28 billion for the quarter, compared to the consensus estimate of $5.29 billion. During the same quarter in the previous year, the firm posted $1.48 EPS. The business’s revenue was up 3.8% compared to the same quarter last year. On average, research analysts expect that Gilead Sciences, Inc. will post 6.6 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, June 13th. This represents a $2.52 annualized dividend and a dividend yield of 3.76%. Gilead Sciences’s dividend payout ratio (DPR) is currently 40.98%.
A number of research analysts have recently weighed in on GILD shares. Oppenheimer set a $85.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a report on Monday, April 22nd. Mizuho set a $88.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Friday, March 22nd. Maxim Group reiterated a “buy” rating and issued a $84.00 target price on shares of Gilead Sciences in a report on Friday, March 29th. Raymond James set a $86.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Tuesday, April 23rd. Finally, Piper Jaffray Companies set a $75.00 target price on shares of Gilead Sciences and gave the stock a “hold” rating in a report on Thursday, March 7th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and fifteen have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $79.54.
In other Gilead Sciences news, Director John Francis Cogan sold 2,700 shares of the business’s stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $65.07, for a total value of $175,689.00. Following the completion of the transaction, the director now directly owns 57,560 shares of the company’s stock, valued at $3,745,429.20. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Richard James Whitley sold 9,534 shares of the business’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $65.48, for a total transaction of $624,286.32. Following the completion of the transaction, the director now directly owns 34,669 shares of the company’s stock, valued at $2,270,126.12. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 28,602 shares of company stock worth $1,863,445. 0.20% of the stock is owned by company insiders.
COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by Modern Readers and is owned by of Modern Readers. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.modernreaders.com/news/2019/06/14/principal-financial-group-inc-sells-171449-shares-of-gilead-sciences-inc-nasdaqgild.html.
Gilead Sciences Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Featured Story: What does earnings per share mean?
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.